Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
A Phase II/III randomized double-blind study comparing the safety and the efficacy of a
weekly administration of 25 mg nebulized AmBisome with nebulized placebo solution to prevent
invasive pulmonary aspergillosis in neutropenic hemato-oncologic patients.